Iqirvo (Elafibranor) Patent Expiration, LOE Window & CMS Spending

Iqirvo (Elafibranor) by Ipsen Biopharmaceuticals: FDA Orange Book LOE 2044-03-05, 0 AB generics, $12.0M 2024 CMS Part D & Medicaid spend, and $11,460 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIpsen Biopharmaceuticals
FDA Application & PathwayN218860 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2044-03-05
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$12.0M
2024 Medicare Part D Spend$9.9M
2024 Medicaid Spend$2.1M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($11,460 intro WAC)